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Abstract 
The synthesis and microbiological evaluation of 7-, 8- and 9-nitro-1,2,4-
trihalogenophenoxazin-3-one substrates with potential in the detection of nitroreductase-
expressing pathogenic microorganisms are described.   The 7- and 9-
nitrotrihalogenophenoxazinone substrates were reduced by most Gram negative 
microorganisms and were inhibitory to the growth of certain Gram positive bacteria; however, 
the majority of Gram positive strains that were not inhibited by these agents, along with the 
two yeast strains evaluated, did not reduce the substrates.  These observations suggest there 
are differences in the active site structures and substrate requirements of the nitroreductase 
enzymes from different strains; such differences may be exploited in the future for 
differentiation between pathogenic microorganisms. The absence of reduction of the 8-
nitrotrihalogenophenoxazinone substrates is rationalized according to their electronic 
properties and correlates well with previous findings.  
 
Keywords: Chromogenic substrates; Nitroreductase; Phenoxazinones; Microbial 
identification  
 
1. Introduction 
The ability of nitroreductase and other enzymes to reduce an aromatic nitro group to the 
corresponding hydroxylamine and/or amine is of significant interest, with great potential for 
biomedical, biocatalyst and bioremediation applications.
1-4 For example, the reduction of a 
nitroaromatic prodrug by a bacterial nitroreductase is central to the GDEPT anticancer 
therapeutic approach,
5,6 for which the mechanism of the Escherichia coli nitroreductase 
activation has been elucidated.
7  
Nitroreductase enzymes have been subdivided
 into two different classes,
8,9 namely type I and 
type II nitroreductases, based on their relative sensitivity to oxygen. The type I nitroreductases 
are oxygen insensitive and can reduce nitro compounds to their corresponding amines via the 
nitroso and hydroxylamine intermediates, using a two electron transfer mechanism.
9-11 With 
the type II nitroreductases, which are oxygen sensitive, the reduction of nitro groups is 
initiated via a single electron transfer process, forming a nitro radical anion, which either 4 
 
accepts a second electron to form the nitroso intermediate and then follows the two electron 
reduction process, or is rapidly reoxidised to a nitro group in the presence of oxygen.
8,9 
The widespread distribution of nitroreductase enzymes in pathogenic bacteria and yeasts 
offers the potential to enhance the detection of such microorganisms in both clinical and food 
applications.
11,12 The successful detection of pathogenic bacteria as a result of their 
nitroreductase action has been demonstrated in over thirty Gram negative and Gram positive 
microorganisms,
11 using the fluorogenic 7-nitrocoumarin-3-carboxylic acid 1a or 7-nitro-4-
methylcoumarin 1b (Figure 1). These compounds emit a strong fluorescent signal upon 
exposure to U.V. light (λ = 365nm) after incubation with the bacteria. Moreover, other 
fluorogenic compounds, such as the 4-nitrobenzylcarbamate derivatives of 7-
aminocoumarins,
13 and derivatives of nitrobenzoxazole 2a, nitrobenzothiazole 2b and 
nitrobenzimidazole 2c (Figure 1), were also shown to respond to nitroreductase activity, 
although with greater selectivity for Gram negative bacteria.
14,15 The extension of this 
approach to chromogenic nitroaromatic substrates, including derivatives of 4-(4'-nitrostyryl)-
pyridine 3a,
16 4-(4'-nitrostyryl)-quinoline 3b
17 and 2-(4'-nitrostyryl)-benzothiazole 3c
18 
(Figure 1), suggests a general application of nitroreductase enzyme substrates as detection 
agents, particularly for Gram negative pathogenic bacteria. It is interesting to note that more 
spatially compact nitroreductase substrates, such as nitrobenzenes and nitrocoumarins 1a and 
1b,
11,13 are reduced by a wider range of both Gram negative and Gram positive bacteria, while 
the more bulky nitroaromatic substrates, for example, the nitrobenzoxazole 2a, 
nitrobenzothiazole 2b and nitrobenzimidazole 2c derivatives, are less well reduced by the 
Gram positive bacteria,
14-18 which may suggest differences in the active sites of Gram 
negative nitroreductases compared to those of Gram positive bacteria. 
 
Figure 1. Examples of established fluorogenic and chromogenic nitroreductase substrates. 5 
 
We previously reported the synthesis and the microbiological evaluation of the chromogenic 
7-aminophenoxazinones 4 and their corresponding aminopeptidase substrates, which indicate 
the presence of certain bacteria by the intense colour released upon bacterial enzymatic 
action.
19 By analogy, the corresponding 7-nitrophenoxazinone was a desirable target substrate 
as a potential marker of nitroreductase activity.  Herein we report the preparation and 
evaluation of 7-, 8- and 9-nitro-1,2,4-trihalogenophenoxazin-3-ones 5-7, (Figure 2), for their 
ability to detect pathogenic microorganisms through nitroreductase activity.  
 
Figure 2. 7-Aminophenoxazin-3-one chromogens 4 and nitrotrihalogenophenoxazinones 5-7. 
 
2. Results and discussion 
2.1 Synthesis 
The nitrotrihalogenophenoxazinones were synthesized using the route described previously 
for the synthesis of 7-nitrohalogenophenoxazinones 5b, 5c and 8-nitro-1,2,4-
trichlorophenoxazinone 6b
20 without modification. With the availability of several 2-
aminonitrophenol isomers, the opportunity was taken to include the synthesis of 8-nitro and 9-
nitrophenoxazinones in this study. Following the general procedure, 2-aminonitrophenols 8-
10 were condensed with tetrahalogeno-1,4-benzoquinones 11a-c in an ethanolic solution 
containing sodium acetate (Scheme 1). 7-Nitro 5a-c, 8-nitro 6a-c and 9-nitro-1,2,4-
trihalogenophenoxazin-3-ones 7a,b were isolated in low to high yield (Table 1). The 
formation of the desired products was confirmed mostly by 
13C NMR spectroscopy, with the 
characteristic C-F coupling observed in the 
13C NMR spectra of fluorinated nitrophenoxazin-
3-ones 5a, 6a and 7a assisting the characterization of these novel products. 6 
 
 
Scheme 1. Synthesis of nitro-1,2,4-trihalogenophenoxazin-3-ones 5-7. Reagents and conditions: i) EtOH, 
NaOAc, RT.    
Table 1. Yields of synthesized nitrohalogenophenoxazin-3-ones substrates 5a-c, 6a-c and 7a,b  
Compound  Nitro group  X  Yield (%)   
    position 
5a    7-    F  12 
5b    7-    Cl  90   
5c    7-    Br  95 
6a    8-    F  39 
6b    8-    Cl  99 
6c    8-    Br  72 
7a    9-    F  15 
7b    9-    Cl  45 
 
The synthesis of fluorinated derivatives 5a, 6a and 7a proved to be problematic and all were 
isolated in poor yield, along with a highly insoluble solid, suspected to be triphenodioxazines 
12a-c, respectively. Spectroscopic evidence for structure 12a was obtained alongside 
nitrophenoxazinone 5a. Mital and Jain have described the formation of triphenodioxazines 
under conditions similar to those described here (Scheme 1).
21 
 
A reaction mechanism for an analogous condensation of various aminophenols with 2,3-
dichloro-1,4-naphthoquinone in an ethanolic solution containing sodium or potassium acetate 
has been reported by Agarwal and Schäfer.
22 Deprotonation of the  nitroaminophenol 8-10 is 
followed by a 1,4-Michael-type nucleophilic attack of the resulting phenoxide on 7 
 
tetrahalogenobenzoquinone 11a-c,  resulting in the formation of  the corresponding 2-
phenoxy-3,5,6-trihalogenoquinones 13a-c, 14a-c and 15a,b. These intermediates then 
undergo ring closure to form the nitro-1,2,4-trihalogenophenoxazin-3-ones 5a-c, 6a-c and 
7a,b (Scheme 2). 
 
Scheme 2. Suggested mechanism for the formation of nitrohalogenophenoxazin-3-ones
19 5a-c, 6a-c and 7a,b. 
2.2 Microbiological evaluation 
The chromogenic substrates 5-7 were evaluated for their suitability as nitroreductase 
substrates for the detection of microbial nitroreductase activity. The reduction of the weakly 
coloured compounds 5-7 by an unspecified nitroreductase was expected to produce the 
corresponding, intensely coloured, aminophenoxazin-3-ones 16a-c, 17a-c and 18a,b. This 
would result in a dramatic and readily visualised change in colour at the site of reduction 
(Scheme 3).  
 
Scheme 3. Expected  nitroreductase enzyme activity and reduction of substrates 5a-c, 6a-c and 7a,b.  
Conditions: i) Bacterial nitroreductase enzymatic activity. 8 
 
The halogenated nitrophenoxazin-3-ones 5-7 were evaluated for their suitability as 
nitroreductase substrates with a range of pathogenic microorganisms from the National 
Collection of Type Cultures (London, UK) and from the Freeman Hospital Microbiology 
Department (Newcastle upon Tyne, UK), including ten Gram negative and eight Gram 
positive strains and two yeasts (Table 2). All of these microorganisms had previously been 
shown to express nitroreductases and to have the ability to reduce a nitro-substituted aromatic 
fluorogenic compound.
11 
Table 2. Reduction of substrates 5-7 by selected clinically relevant Gram positive and Gram negative bacteria, 
and yeasts. 
________________________________________________________________________________________________ 
      Substrate
a  5a  5b  5c  6a  6b  6c  7a  7b 
Bacterial Strain     Reference    Visualization of colouration after 24 hours
b 
Gram negative bacteria 
1 Escherichia coli    NCTC 10418  +
c  +  +  -  -  -  +  + 
2 Serratia marcescens  NCTC 10211  +  +  +  -  -  -  +  + 
3 Pseudomonas aeruginosa  NCTC 10662  +  +  -  -  -  -  +  - 
4 Burkholderia cepacia  LMG 1222  -  -  -  -  -  -  -  - 
5 Yersinia enterocolitica  NCTC 11176  +  -  -  -  -  -  -  + 
6 Salmonella typhimurium  NCTC 74    +  +  +  -  -  -  +  + 
7 Citrobacter freundii  Wild type 46262  +  +  -  -  -  -  +  + 
8 Morganella morganii  Wild type 462403  +  +  +  -  -  -  +  + 
9 Enterobacter cloacae  NCTC 11936  +  +  +  -  -  -  +  + 
10 Providencia rettgeri  NCTC 7475  +  +  +  -  -  -  +  + 
 
Gram positive bacteria 
11 Bacillus subtilis   NCTC 9372  NG
d  -  -  NG  -  -  NG  - 
12 Enterococcus faecalis  NCTC 775  -  -  -  NG  -  -  -  + 
13 Enterococcus faecium  NCTC 7171  -  -  -  NG  -  -  -  - 
14 Staphylococcus  
      epidermidis     NCTC 11047  NG  NG  NG  NG  -  NG  NG  NG 
15 Staphylococcus aureus  NCTC 6571  NG  NG  NG  NG  -  -  NG  NG 
16 Staphylococcus aureus  
      (MRSA)    NCTC 11939  NG  -  -  NG  -  -  NG  + 
17 Streptococcus pyogenes  NCTC 8306  NG  NG  NG  NG  NG  -  NG  NG 
18 Listeria  monocytogenes  NCTC 11994  +  -  -  NG  -  -  -  - 
 
Yeasts 
19 Candida albicans  ATCC 90028  -  -  -  NG  -  -  NG  - 
20 Candida glabrata  NCPF 3943  -  -  -  NG  -  -  -  - 
____________________________________________________________________________________________________ 
aEach substrate was tested at a concentration of 50 mg/L. 9 
 
bResults after 24h of incubation at 37°C. 
cPositive indicates colour observed; negative indicates no colour observed. 
dNG, no growth. 
 
None of the substrates were toxic to the Gram negative bacteria and growth was observed in 
the presence of all substrates; however, toxicity was observed towards some of the Gram 
positive bacteria and yeasts, resulting in the inhibition of the growth of these organisms. The 
most toxic substrate was 8-nitro-1,2,4-trifluorophenoxazin-3-one 6a, which was universally 
toxic to all Gram positive bacteria and the yeasts, while 9-nitro-1,2,4-trifluorophenoxazin-3-
one 7a was toxic to most of these strains and 7-nitro-1,2,4-trifluorophenoxazin-3-one 5a also 
exhibited toxicity across many of the Gram positive bacteria. The growth of the two 
Enterococcal strains tested and Listeria monocytogenes (No. 18) was not inhibited by any of 
the substrates except 6a. The trifluorinated derivatives 5a, 6a and 7a were the most toxic 
compounds in the series. 
 
Most Gram negative bacteria successfully reduced substrates 5a-c and substrates 7a,b. The 
enzymatic activity was witnessed by the generation of a red to orange colouration in the 
bacterial colonies for substrates 5a-c, brown for substrate 7a and lilac for substrate 7b. The 
most encouraging results were obtained with 7-nitro-1,2,4-trifluorophenoxazinone 5a, as this 
substrate produced the brightest and most strongly contrasting colour in the bacterial colonies, 
with minimal diffusion into the medium (Figure 3). Absence (or low diffusion) of the reduced 
substrate in the medium is essential for distinction and accurate localization of individual 
bacterial colonies expressing nitroreductase enzymes when several microorganisms are 
present in the culture medium.  10 
 
 
Figure 3. (a) Inoculation pattern, referenced to the numbers of strains in Table 2; (b) Screening of 7-nitro-1,2,4-
trifluorophenoxazinone 5a with ten Gram negative and eight Gram positive bacterial strains, and two yeasts. 
None of these substrates were reduced at all by Burkholderia cepacia (No. 4), which can also 
metabolise certain nitroaromatic compounds, such as 2,4-dinitrotoluene, by an alternative 
defined oxidative pathway, leading to oxidative cleavage of the aromatic system.
23 
Burkholderia species exhibit high level intrinsic resistance to many antibacterial agents, even 
to colistin and gentamicin, due to their particularly impermeable membrane,
24-27 so these 
substrates may not even reach the cytoplasm, where nitroreductase activity would be expected 
to occur. Burkholderia cepacia (No. 4) was the only Gram negative strain that did not reduce 
7-nitro-1,2,4-trifluorophenoxazin-3-one 5a and thus distinguishes this bacterium from the 
other pathogenic strains tested.  This substrate 5a also differentiates Listeria monocytogenes 
(No. 18) from the other Gram positive strains, being the only substrate reduced by this 
bacterium. 
The chlorinated and brominated derivatives of 7-nitrophenoxazinone 5b and 5c and the 
chlorinated derivative of 9-nitrophenoxazinone 7b are able to differentiate MRSA (No. 16) 
from β-lactam susceptible Staphylococcus aureus (No. 15) and Staphylococcus epidermidis 
(No. 14); of these three strains, only MRSA was not inhibited by substrates 5b, 5c and 7b. 
Although few of the Gram positive bacteria and the yeasts were unable to reduce the nitro 11 
 
substrates, it was not due to a lack of expression of nitroreductase, as it has been previously 
shown that they reduce other nitroreductase substrates.
11   
The three 8-nitrophenoxazinone substrates 6a-c were not reduced by nitroreductases from 
Gram negative bacteria, unlike their analogues 5a-c and 7a,b, despite good bacterial growth 
(Table 2). Catalytic reduction of the 8-nitrophenoxazinones 6a-c using hydrogen and either 
Pd/C or PtO2, followed by re-oxidation of the initial aminophenol product (19a-c) with 
manganese (IV) oxide, produced deeply coloured 8-aminophenoxazinones (17a-c), of which 
the most soluble example, 1,2,4-trifluoro-8-aminophenoxazin-3-one 17a, was isolated and 
characterized (Scheme 4). The lack of any colour after incubation of the 8-
nitrophenoxazinones 6a-c with bacteria thus provides evidence that the three compounds were 
not substrates for nitroreductase activity. 
 
Scheme 4. Catalytic reduction of 8-nitrophenoxazinones 6a-c and oxidation of the resulting aminophenols 19a-c 
to 8-aminophenoxazinones 17a-c. 
Reagents and conditions: i) H2, Pd/C 10% or PtO2
a, EtOAc : MeOH (1:1); ii) MnO2, MeOH. 
aUsed for the reduction of 6c. 
 
Early work by McCormick
28 and later studies by Kitamura,
29 testing a wide range of variously 
substituted nitrocompounds for their suitability as nitroreductase substrates, showed that the 
position of the nitro group with respect to other substituents, alongside their electronic 
properties, is a determining factor in the bacterial reduction of nitroaromatic compounds. For 
example, nitroreductase activity was generally higher for nitrobenzenes bearing a para-
electron withdrawing group. Consideration of the substituents at the para-position to the nitro 
group in each of the present substrates reveals that compounds 5a-c, with the nitro group in 
the 7-position, have the electron withdrawing quinone-imine system in the para-position. In 
compounds 7a,b, the 9-nitro group is conjugated at the ortho-position to the quinone-imine 
system and C9 may be considered to be similarly electron deficient to C7 in 5a-c. Conversely, 
in compounds 6a-c, the 8-nitro group is para to the potentially electron releasing ether 12 
 
oxygen. Overall then, the electron density at C8 in the case of substrates 6a-c can be expected 
to be considerably higher than C7 and C9 in the case of substrates 5a-c and 7a,b, respectively. 
The electron withdrawing effect of the quinone-imine portion of the phenoxazinone ring 
affects the 7- and 9-positions primarily and would thus be expected to facilitate the reduction 
of substrates 5 and 7 (Scheme 5),   the oxygen bridging atom can contribute to some extent to 
the higher electron density at the 8-position, thereby reducing the propensity for reduction of 
substrates 6a-c (Scheme 5).  
 
Scheme 5. Key resonance forms that contribute to differentiation of nitroreductase activity in (a) 7-
nitrohalogenophenoxazin-3-ones 5a-c, and  (b) 8-nitrohalogenophenoxazin-3-ones 6a-c  
 
The 
13C NMR data provide support for these electronic differences (Table 3): in compounds 
5a-c and 7a,b, the chemical shifts of C7 and C9, respectively, show greater deshielding than 
C8 of the corresponding halogenated compounds 6a-c. 
Table 3. 
13C NMR data for C-NO2 of  nitrotrihalogenophenoxazin-3-ones 5a-c, 6a-c, and 7a,b 
 
    Chemical shift of C bearing nitro group (d6-DMSO; δ / ppm) 
Compound   C-NO2    a X = F     b X = Cl  c X = Br 
5  C7    149.1  (147.9
a)   149.8    149.7 
6  C8    145.2  (143.4
a)   145.3    145.3 
              7  C9    147.8  (146.4
a)   147.8    N.D.
b 
a NMR solvent was THF-d8. 
b N.D.: not done.  
These observations correlate well with Kitamura’s experiments
29 and help to explain the 
absence of visible reduction for substrates 6a-c, while substrates 5a-c and 7a,b were reduced 
to some extent. 13 
 
 
3. Conclusions 
Although some substrate selectivity has been previously observed with the nitroreductase 
from the food and gastrointestinal bacterium, Lactobacillus plantarum
30, the differences in the 
reduction of the substrates, particularly by the bacteria used in the current work, suggest that, 
rather than detecting a wide range of Gram negative and Gram positive microorganisms, 
nitroreductase activity on substituted 7- or 9-nitrophenoxazinones could be used to distinguish 
certain pathogenic strains. Furthermore, differences in the nitroreductase enzymes, or in the 
nitro group metabolic pathways, between strains can be inferred by the variations in reduction 
of a particular nitroaromatic substrate. 
The 8-nitro-1,2,4-trihalogenophenoxazin-3-ones 6a-c proved to be unsuitable for the detection 
of bacterial nitroreductase; the electronic factors associated with the position of the 8-nitro 
group on the phenoxazin-3-one ring appear to be very unfavourable for enzymatic reduction. 
These observations correlate with results previously published.
28,29 
7-Nitro-1,2,4-trihalogenophenoxazin-3-ones 5a-c and 9-nitro-1,2,4-trihalogenophenoxazin-3-
ones 7a,b showed positive results for the general detection of Gram negative bacterial 
nitroreductase, excepting Burkholderia cepacia, which was distinguished by its lack of 
reduction of 7-nitro-1,2,4-trifluorophenoxazin-3-one 5a. Exploration and exploitation of the 
differences in substrate structure and properties, such as replacement of the halogen atoms by 
other substituents, could reduce the toxicity of the substrates and improve enzymatic 
reduction. Such modifications could also assist in distinguishing pathogenic strains by 
conferring even greater selectivity for the nitroreductase enzymes of particular 
microorganisms. 
4. Experimental section 
4.1. General methods 
All commercially available reagents and solvents were obtained from Sigma-Aldrich, Fluka 
or Riedel-de-Haan and were used without further purification. Melting points were recorded 
on a Reichart-Kofler hot-stage microscope apparatus and are uncorrected.  Infrared spectra 
were recorded in the range 4000 – 600 cm
-1 using a Perkin Elmer Spectrum BX FT-IR 
instrument with internal calibration and a Pike sampling system.  NMR spectra were obtained 
using a Bruker Ultrashield 300 spectrometer at 300 MHz for 
1H spectra, 75 MHz for 
13C 14 
 
spectra or at 282 MHz for 
19F spectra or a Bruker Ultrashield 500 spectrometer at 500 MHz 
for 
1H spectra or at 125 MHz for 
13C spectra. High-resolution mass spectra were obtained 
from the EPSRC National Mass Spectrometry Facility Swansea, using a Thermofisher LTQ 
Orbitrap XL. Elemental analyses were performed using an Exeter Analytical CE-440 
Elemental Analyzer. 
 
4.2. Synthesis of nitrohalogenophenoxazin-3-ones 5-7: general procedure
20,31 
2-Aminonitrophenol 8-10 (1 mol equivalent), p-tetrahalogenobenzoquinone 11a-c (1.1 mol 
equivalent) and sodium acetate (1.2 mol equivalent) were suspended in ethanol. The solution 
was stirred for 24 hours or until no more 2-aminonitrophenol was detected by TLC. For the 
brominated and chlorinated derivatives, a red precipitate progressively appeared as the 
reaction neared completion. Water was then added to precipitate completely the red solid out 
of solution. The solid was recovered by filtration and washed with water and a little ethanol, 
then either recrystallised from acetic acid or purified by column chromatography. 
4.2.1. 7-Nitro-1,2,4-trifluoro-3H-phenoxazin-3-one (5a) and 3,10-dinitro-6,13-
difluorotriphenodioxazine (12a). The title compounds were prepared from p-fluoranil 11a 
(1.90 g, 10.57 mmol) and 2-amino-5-nitrophenol 8 (1.42 g, 9.61 mmol) according to the 
general procedure. Water (100 mL) was added to the reaction mixture and the resulting 
mixture was extracted with EtOAc (3 × 60 mL). The emulsion was filtered through a sintered 
funnel and the insoluble residue was washed several times with EtOAc, giving 12a as a dark 
violet solid (1.91g, 4.63mmol, 48%). Dark violet microcrystalline solid was obtained from 
nitrobenzene, mp: 315°C (dec.); (found: (MH)
+, 413.0324. Calc. for C18H7F2N4O6: (MH)
+, 
413.0328); νmax/cm
-1 3104 (C-H), 1622 (C=N), 1595 and 1579 (C=C), 1515 and 1332 (NO2). 
The aqueous layer was discarded and the combined EtOAc filtrates and layers were washed 
with water (150 mL) and brine (150 mL), and dried (MgSO4). The solvent was removed in 
vacuo and the residue subjected to column chromatography on silica, eluting with petroleum 
ether 60-80°C : EtOAc (80 : 20). 5a was isolated as a dark purple solid (0.35 g, 1.19 mmol, 
12%). Dark red-purple needle-like crystals were obtained from glacial acetic acid, mp: 218-
220°C; (found: C, 48.5; H, 1.05; N, 9.15%. C12H3F3N2O4 requires C, 48.7; H, 1.0; N, 9.5%); 
(found: (MH)
+, 297.0118. Calc. for C12H4F3N2O4: (MH)
+, 297.0118); νmax/cm
-1 3104 (C-H), 
1660 (C=O), 1596 (C=C), 1531 and 1312 (NO2), 1003 (C-F); δH (300 MHz, THF-d8) 6.41 
(1H, d, J = 8.7 Hz, 9-H), 6.58 (1H, dd, J = 8.7, 2.4 Hz, 8-H), 6.74 (1H, d, J = 2.4 Hz, 6-H); δC 
(75 MHz, THF-d8) 110.3 (CH, 6-C), 118.6 (CH, 8-C), 129.4 (CH, 9-C), 130.1 (quat., ddd, J = 
8.5, 5.2, 1.4 Hz, 10a-C), 134.1 (quat., 9a-C), 136.0 (quat., dd, J = 262.7, 6.1 Hz, 4-C), 141.3 15 
 
(quat., dt, J = 273.4, 6.9 Hz, 2-C), 142.2 (quat., dd,  J = 273.4, 12.2 Hz, 1-C), 141.4 (quat., d, 
J = 1.5 Hz, 5a-C), 141.7 (quat., ddd, J = 18.1, 4.8, 1.2 Hz, 4a-C), 147.9 (quat., 7-C), 166.7 
(quat., td, J = 21.4, 5.4 Hz, 3-C); δF (282 MHz, THF-d8) -282.17 (1F, t, J = 2.3 Hz, 4-F), -
271.89 (1F, dd, J = 9.3, 2.0 Hz, 2-F), -265.41 (1F, dd, J = 9.3, 2.0 Hz, 1-F); δH (300 MHz, d6-
DMSO) 8.23 (1H, d, J = 8.7 Hz, 9-H), 8.31 (1H, dd, J = 8.7, 2.4 Hz, 8-H), 8.54 (1H, d, J = 2.4 
Hz, 6-H); δC (75 MHz, d6-DMSO) 112.3 (CH, 6-C), 120.8 (CH, 8-C), 131.4 (CH, 9-C), 132.1 
(quat., dd, J =9.4, 3.0 Hz, 10a-C), 135.4 (quat., 9a-C), 136.0 (quat., dd, J = 262.7, 6.1 Hz, 4-
C), 142.6 (quat., dt, J = 268.2, 6.1 Hz, 2-C), 143.6 (quat., dd,  J = 270.4, 11.7 Hz, 1-C), 142.5 
(quat., 5a-C), 141.7 (quat., ddd, J = 18.1, 4.8, 1.2 Hz, 4a-C), 149.1 (quat., 7-C), 168.9 (quat., 
td, J = 20.3, 5.6 Hz, 3-C); δF (282 MHz, d6-DMSO) -280.43 (1F, s, 4-F), -268.27 (1F, d, J = 
11.9 Hz, 2-F), -263.04 (1F, d, J = 11.3 Hz, 1-F). 
4.2.2. 7-Nitro-1,2,4-trichloro-3H-phenoxazin-3-one (5b).
32 The title compound was prepared 
from p-chloranil 11b (3.52 g, 14.32 mmol) and 2-amino-5-nitrophenol 8 (1.97 g, 12.78 
mmol); 5b was isolated as a purple solid (4.06 g, 11.75 mmol, 90%). Purple lustrous plates of 
5b were obtained from glacial acetic acid; mp: 239-241°C [lit.: 238-240°C
32 (from AcOH)]; 
(found: C, 41.7; H, 0.9; N, 7.9%. C12H3Cl3N2O4 requires: C, 41.7; H, 0.9; N 8.1%); (found: 
(MH)
+, 344.9226. Calc. for C12H3
35Cl3N2O4: (MH)
+, 344.9231; found: (MH)
+, 346.9195. Calc. 
for C12H3
35Cl2
37ClN2O4: (MH)
+, 346.9202; found: (MH)
+, 348.9162. Calc. for C12H3
35Cl 
37Cl2N2O4: (MH)
+, 348.9172); νmax/cm
-1 3094 (C-H), 1646 (C=O), 1584 (C=C), 1519 and 
1347 (NO2); δH (300 MHz, d6-DMSO) 8.24 (1H, d, J = 8.7 Hz, 9-H), 8.32 (1H, dd, J = 8.7, 2.4 
Hz, 8-H), 8.51 (1H, d, J = 2.4 Hz, 6-H); δC (75 MHz, d6-DMSO) 111.6 (quat., 4-C), 112.7 
(CH, 6-C), 121.5 (CH, 8-C), 132.1 (CH, 9-C), 136.6 (quat., 5a-C), 137.2 (quat.,1-C or 2-C), 
138.5 (quat., 1-C or 2-C), 143.5 (quat., 9a-C), 146.4 (quat., 2 × C, 4a-C and 10a-C), 149.8 
(quat., 7-C), 171.0 (quat., 3-C). 
4.2.3. 7-Nitro-1,2,4-tribromo-3H-phenoxazin-3-one (5c). The title compound was prepared 
from p-bromanil 11c (1.03 g, 2.42 mmol) and 2-amino-5-nitrophenol 8 (0.34 g, 2.20 mmol); 
5c was isolated as a bright red solid (1.10 g, 2.30 mmol, 95.0%). A microcrystalline dark red 
solid of 5c was obtained from glacial acetic acid, mp: 263-264°C; (found: C, 30.1; H, 0.7; N, 
5.6%. C12H3Br3N2O4 requires: C, 30.1; H, 0.6; N 5.85%); (found: (MH)
+, 476.7714. Calc. for 
C12H3
79Br3N2O4: (MH)
+, 476.7716; found: (MH)
+, 478.7692. Calc. for C12H3
79Br2 
81BrN2O4: 
(MH)
+, 478.7696; found: (MH)
+, 480.7669. Calc. for C12H3
79Br
81Br2N2O4: (MH)
+, 480.7676; 
found: (MH)
+, 482.7646. Calc. for C12H3
81Br3N2O4: (MH)
+, 482.7658); νmax/cm
-1 3101 (C-H), 
1641 (C=O), 1529 and 1346 (NO2); δH (300 MHz, d6-DMSO) 8.21 (1H, d, J = 9.0 Hz, 9-H), 
8.29 (1H, dd, J = 8.7, 2.4 Hz, 8-H), 8.44 (1H, d, J = 2.4 Hz, 6-H); δC (75 MHz, d6-DMSO) 16 
 
103.2 (quat., 4-C), 112.5 (CH, 6-C), 121.4 (CH, 8-C), 131.9 (CH, 9-C), 134.9 (quat., 1-C or 2-
C), 137.0 (quat., 1-C or 2-C), 137.1 (quat., 5a-C), 143.6 (quat., 9a-C), 147.2 (quat., 4a-C or 
10a-C), 148.3 (quat.,  4a-C or 10a-C), 149.7 (7-C), 171.5 (quat., 3-C). 
4.2.4. 8-Nitro-1,2,4-trifluoro-3H-phenoxazin-3-one (6a). The title compound was prepared 
from p-fluoranil 11a (1.51 g, 8.39 mmol) and 2-amino-4-nitrophenol 9 (1.27 g, 8.22 mmol) 
according to the general procedure. The precipitate was taken into EtOAc (100 mL) and the 
resulting mixture filtered through a sintered funnel. The insoluble residue was washed several 
time with EtOAc and discarded. The combined organic filtrates were washed with 10% aq. 
NaOH solution (4 x 100 mL) and water (1 x 100 mL), and dried (MgSO4). The solvent was 
removed under reduced pressure and the residue subjected to column chromatography, eluting 
with a gradient mixture of petroleum ether 60-80°C : Et2O (50:50 to 0:100). Compound 6a 
was isolated as a red solid (0.94 g, 3.17 mmol, 38.5%). An orange crystalline solid of 6a was 
obtained from glacial acetic acid, mp: 212-214°C; (found: C, 48.6; H, 1.05; N, 9.1%. 
C12H3F3N2O4 requires C, 48.7; H, 1.0; N, 9.5%); m/Z 295.9 (M)
-; νmax/cm
-1 3093 (C-H), 1648 
(C=O), 1608 (C=C), 1518 and 1308 (NO2), 1004 (C-F); δH  (300 MHz, THF-d8) 6.03 (1H, d, J 
= 9.3 Hz, 6-H), 6.80 (1H, dd, J = 9.0, 2.7 Hz, 7-H), 7.06 (1H, d, J = 2.7 Hz, 9-H); δC (75 
MHz, THF-d8) 115.4 (CH, 6-C), 123.8 (CH, 9-C), 126.2 (CH, 7-C), 129.9 (quat., ddd, J = 9.6, 
5.1, 1.3 Hz, 10a-C), 130.2 (quat., 9a-C), 136.0 (quat., dd, J = 262.4, 6.5 Hz, 4-C), 141.3 
(quat., dt, J = 272.7, 6.9 Hz, 2-C), 142.2 (quat., dd, J = 273.9, 12.0 Hz, 1-C), 140.8 (quat., 
ddd, J = 18.3, 5.5, 1.1 Hz, 4a-C), 143.4 (quat., 8-C), 145.3 (quat., d, J = 1.6 Hz, 5a-C), 166.8 
(quat., td,   J = 21.0, 5.6 Hz, 3-C); δF (282 MHz, THF-d8) -282.05 (1F, t, J = 2.8 Hz, 4-F), -
271.73 (1F, dd, J = 9.6, 1.7 Hz, 2-F), -266.07 (1F, dd, J = 9.3, 2.5 Hz, 1-F); δH  (300 MHz, d6-
DMSO) 7.93 (1H, d, J = 9.0 Hz, 6-H), 8.56 (1H, dd, J = 9.0, 2.4 Hz, 7-H), 8.76 (1H, d, J = 2.4 
Hz, 9-H); δC (75 MHz, d6-DMSO) 118.4 (CH, 6-C), 125.9 (CH, 9-C), 129.0 (CH, 7-C), 132.1 
(quat., 9a-C), 132.5 (quat., dd, J = 8.8, 5.2 Hz, 10a-C), 137.8 (quat., dd, J = 256.3, 6.45 Hz, 4-
C), 143.2 (quat., dt, J = 267.75, 6.8 Hz, 2-C), 144.2 (quat., dd, J = 270.4, 11.9 Hz, 1-C), 142.8 
(quat., d, J = 14.1 Hz, 4a-C), 145.2 (quat., 8-C), 147.3 (quat., 5a-C), 169.5 (quat., td, J = 20.0, 
4.9 Hz, 3-C); δF (282 MHz, d6-DMSO) -279.65 (1F, s, 4-F), -268.13 (1F, d, J = 11.3 Hz, 2-F), 
-264.22 (1F, d, J = 11.8 Hz, 1-F). 
4.2.5. 8-Nitro-1,2,4-trichloro-3H-phenoxazin-3-one (6b).
21 The title compound was prepared 
from p-chloranil 11b (1.74 g, 7.07 mmol) and 2-amino-4-nitrophenol 9 (0.991 g, 6.43 mmol); 
6b was isolated as a red solid (2.19 g, 6.34 mmol, 99%). Red plates of 6b were obtained from 
glacial acetic acid; mp: 261-263°C [lit.: 248-250°C
21 (from acetone)]; (found: C, 41.7; H, 0.9; 
N, 7.9%. C12H3Cl3N2O4 requires: C, 41.7; H, 0.9; N 8.1%); (found: (MH)
+, 344.9229. Calc. 17 
 
for C12H3
35Cl3N2O4: (MH)
+, 344.9231; found: (MH)
+, 346.9197. Calc. for 
C12H3
35Cl2
37ClN2O4: (MH)
+, 346.9202; found: (MH)
+, 348.9164. Calc. for C12H3
35Cl 
37Cl2N2O4: (MH)
+, 348.9172); νmax/cm
-1 3088 (C-H), 1649 (C=O), 1597 (C=C), 1510 and 
1331 (NO2); δH  (300 MHz, d6-DMSO) 7.95 (d, 1H, J = 9.0 Hz, 6-H), 8.57 (dd, 1H, J = 9.0, 
2.7 Hz, 7-H), 8.73 (d, 1H, J = 2.7 Hz, 9-H); δC (75 MHz, d6-DMSO) 111.8 (quat., 4-C), 118.3 
(CH, 6-C), 125.9 (CH, 9-C), 129.1 (CH, 7-C), 132.6 (quat., 9a-C), 137.2 (quat., 1-C or 2-C), 
138.2 (quat., 1-C or 2-C), 145.3 (quat., 8-C), 145.6 (quat.,  4a-C or 10a-C), 146.2 (quat., 4a-C 
or 10a-C), 147.7 (quat., 5a-C), 171.1 quat., 3-C). 
4.2.6. 8-Nitro-1,2,4-tribromo-3H-phenoxazin-3-one (6c).
21 The title compound was prepared 
from p-bromanil 11c (4.05 g, 9.57 mmol) and 2-amino-4-nitrophenol 9 (1.34 g, 8.70 mmol). 
Elution with petroleum ether 60-80°C : EtOAc (60:40) gave 6c as a red solid (3.01 g, 6.29 
mmol, 72%). Lustrous cardinal red crystals of 6c were obtained from glacial acetic acid, mp: 
285-287°C [lit.: 287°C
21 (from acetone)]; found: C, 30.1; H, 0.6; N, 5.6%. C12H3Br3N2O4 
requires: C, 30.1; H, 0.6; N 5.85%); (found: (MH)
+, 476.7716. Calc. for C12H3
79Br3N2O4: 
(MH)
+, 476.7716; found: (MH)
+, 478.7694. Calc. for C12H3
79Br2 
81BrN2O4: (MH)
+, 478.7696; 
found: (MH)
+, 480.7670. Calc. for C12H3
79Br
81Br2N2O4: (MH)
+, 480.7676; found: (MH)
+, 
482.7646. Calc. for C12H3
81Br3N2O4: (MH)
+, 482.7658); νmax/cm
-1 3078 (C-H), 1638 (C=O), 
1581 (C=C), 1508 and 1328 (NO2); δH  (300 MHz, d6-DMSO) 7.82 (1H, d, J = 9.0 Hz, 6-H), 
8.47 (1H, dd, J = 9.3, 2.7 Hz, 7-H), 8.60 (1H, d, J = 2.7 Hz, 9-H); δC (75 MHz, d6-DMSO) 
103.4 (quat., 4-C), 118.1 (CH, 6-C), 125.6 (CH, 9-C), 129.0 (CH, 7-C), 133.0 (quat., 9a-C), 
134.8 (quat., 1-C or 2-C), 136.5 (quat., 1-C or 2-C), 145.3 (quat., 8-C), 146.5 (quat., 4a-C or 
10a-C), 147.9 (quat., 4a-C or 10a-C), 148.2 (quat., 5a-C), 171.6 (quat., 3-C). 
4.2.7. 9-Nitro-1,2,4-trifluoro-3H-phenoxazin-3-one (7a). The title compound was prepared 
from p-fluoranil 11c (0.90 g, 5.00 mmol) and 2-amino-3-nitrophenol 10 (0.74 g, 4.82 mmol) 
according to the general procedure. The precipitate was taken into EtOAc (100 mL) and the 
resulting mixture filtered through a sintered funnel. The insoluble residue was washed several 
time with EtOAc and discarded. The combined organic filtrates were washed with water (1 x 
100 mL), brine (1 x 100 mL) and dried (MgSO4). The solvent was removed under reduced 
pressure and the residue subjected to column chromatography, eluting with petroleum ether 
60-80°C : EtOAc (80 : 20). 7a was isolated as a dark red solid (0.22 g, 0.73 mmol, 15%). 
Ruby red prisms of 7a with a metallic lustre were obtained from glacial acetic acid, mp: 216-
218°C; (found: C, 48.5; H, 1.0; N, 9.2%. C12H3F3N2O4 requires C, 48.7; H, 1.0; N, 9.5%); 
(found: (MH)
+, 297.0118. Calc. for C12H4F3N2O4: (MH)
+, 297.0118); νmax/cm
-1 3084 (C-H), 18 
 
1649 (C=O), 1603 (C=C), 1530 and 1313 (NO2), 1004 (C-F); δH  (300 MHz, THF-d8) 6.04-
6.13 (m, 3H, 6-H, 7-H and 8-H); δC (75 MHz, THF-d8) 117.6 (CH, 8-C), 117.9 (CH, 6-C), 
123.0 (quat., 9a-C), 130.0 (quat., ddd, J = 10.0, 5.0, 1.2 Hz, 10a-C), 131.5 (CH, 7-C), 135.8 
(quat., dd, J = 261.9, 6.3 Hz, 4-C), 140.7 (quat., ddd, J = 18.2, 4.8, 1.2 Hz, 4a-C), 141.4 
(quat., dt, J = 273.2, 6.8 Hz, 2-C), 141.5 (quat., d, J =1.7 Hz, 5a-C), 142.1 (quat., dd, J = 
274.7, 12.2 Hz, 1-C), 146.4 (quat., 9-C), 166.7 (quat., td, J = 21.1, 5.5 Hz, 3-C); δF (282 MHz, 
THF-d8) -282.53 (1F, t, J = 2.3 Hz, 4-F), -271.43 (1F, dd, J = 9.0, 2.3 Hz, 1-F), -265.36 (1F, 
dd, J = 9.3, 2.3 Hz, 2-F); δH  (300 MHz, d6-DMSO) 7.95 (1H, t, J = 8.4 Hz, 7-H), 8.01 (1H, 
dd, J = 8.4, 1.8 Hz, 8-H), 8.08 (1H, dd, J = 7.5, 1.8 Hz, 6-H); δC (75 MHz, d6-DMSO) 120.5 
(CH, 8-C), 120.7 (CH, 6-C), 124.8 (quat., 9a-C), 132.8 (quat., dd, J = 9.0, 4.5 Hz, 10a-C), 
134.6 (CH, 7-C), 137.5 (quat., dd, J = 255.0, 6.0 Hz, 4-C), 142.7 (quat., ddd, J = 17.3, 4.5, 1.5 
Hz, 4a-C), 143.2 (quat., d, J = 0.8 Hz, 5a-C), 143.3 (quat., dt, J = 267.8, 7.5 Hz, 2-C), 144.0 
(quat., dd, J = 270.0, 10.5 Hz, 1-C), 147.8 (quat., 9-C), 169.4 (quat., td, 21.0, 6.0 Hz, 3-C); δF 
(282 MHz, d6-DMSO) -280.98 (1F, t, J = 2.3 Hz, 4-F), -268.59 (1F, dd, J = 11.0, 2.3 Hz, 1-F), 
-262.77 (1F, dd, J = 11.0, 2.3 Hz, 2-F).  
4.2.8. 9-Nitro-1,2,4-trichloro-3H-phenoxazin-3-one (7b). The title compound was prepared 
from p-chloranil 11c (1.17 g, 7.61 mmol) and 2-amino-3-nitrophenol 10 (1.07 g, 6.92 mmol); 
7b was isolated as a dark purple solid (1.08 g, 3.1 3mmol, 45%). Lustrous deep purple needles 
of 7b were obtained from glacial acetic acid, mp: 254-258°C; (found: C, 41.6; H, 0.9; N, 
7.8%. C12H3Cl3N2O4 requires C, 41.7; H, 0.9; N, 8.1%); (found: (MH)
+, 344.9227. Calc. for 
C12H3
35Cl3N2O4: (MH)
+, 344.9231; found: (MH)
+, 346.9197. Calc. for C12H3
35Cl2
37ClN2O4: 
(MH)
+, 346.9202; found: (MH)
+, 348.9165. Calc. for C12H3
35Cl 
37Cl2N2O4: (MH)
+, 348.9172); 
νmax/cm
-1 3100 (C-H), 1647 (C=O), 1590 (C=C), 1532 and 1331 (NO2); δH  (300 MHz, d6-
DMSO) 7.97 (1H, t, J = 8.4 Hz, 7-H), 8.02 (1H, dd, J = 8.4, 2.1 Hz, 8-H), 8.09 (1H, dd, J = 
7.5, 2.1 Hz, 6-H); δC (75 MHz, d6-DMSO) 111.2 (quat., 4-C), 120.6 (CH, 8-C), 120.8 (CH, 6-
C), 125.3 (quat., 9a-C), 134.6 (CH, 7-C), 136.9 (quat., 1-C or 2-C), 138.6 (quat., 1-C or 2-C), 
143.7 (quat., 5a-C), 145.5 (quat., 4a-C or 10a-C), 146.3 (quat., 4a-C or 10a-C), 147.8 (quat., 
9-C), 171.0 (quat., 3-C). 
 
4.3. Catalytic hydrogenation of 8-nitrohalogenophenoxazin-3-ones 6a-c: general procedure 
Nitro-1,2,3-trihalogeno-3H-phenoxazin-3-ones  6a-c were dissolved in a solvent mixture of 
EtOAc : MeOH (1:1) and either Pd/C 10% or PtO2 (10% of the reactant mass) was added to 
the solution. The reaction mixture was then hydrogenated for 2 to 20 hours, the initial 
hydrogen pressure being set at 2.4bars. Hydrogenation was continued until the hydrogen 19 
 
pressure was steady, after which the catalyst was removed from the reaction mixture by 
filtration through Celite 451. The Celite cake was washed several times with methanol. MnO2 
(3 mol equivalent) was added to the clear solution and the resulting mixture stirred until no 
more amino-3-hydroxyphenoxazine was observed by TLC. The reaction mixture changed to a 
deep colour, ranging from blue to blue-violet, and was again filtered through Celite 451 to 
remove inorganic insoluble materials and the cake was washed several times with THF, until 
the filtrate was clear of colour. The solvent mixture was evaporated in vacuo and the residue 
was subjected to column chromatography on silica. 
4.3.1. 8-Amino-1,2,4-trifluoro-3H-phenoxazin-3-one (17a) 
The title compound was prepared from 8-nitro-1,2,3-trifluoro-3H-phenoxazin-3-one 6a (0.38 
g, 1.29 mmol) using Pd/C 10%. Elution used a gradient mixture of petroleum ether (60-80°C) 
: EtOAc (30:70 to 10:90). 8-Amino-1,2,4-trifluoro-3H-phenoxazin-3-one 17a was isolated as 
a dark violet solid (0.34 g, 1.27 mmol, 98.0 %); m.p. : 277°C (dec.); (found: C, 54.2; H, 2.1; 
N, 10.1%. C12H5F3N2O2 requires C, 54.15; H, 1.9; N, 10.5%); (found: (MH)
+, 267.0373. Calc. 
for C12H6F3N2O2: (MH)
+, 267.0376); νmax/cm
-1 3503, 3358 and 3230 (NH2), 1638 (C=O), 
1610, 1575 and 1513 (C=C), 1002 (C-F); δH  (500 MHz, d1-TFA) 8.17 (1H, d, J = 9.0 Hz, 6-
H), 8.35 (1H, dd, J = 9.0, 2.0 Hz, 7-H), 8.74 (1H, d, J = 1.5 Hz, 9-H); δC (125 MHz, d1-TFA) 
119.1 (CH, 6-C), 125.7 (CH, 9-C), 127.1 (quat., 9a-C), 129.4 (CH, 7-C), 132.5 (quat., dd, J = 
16.5, 3.9 Hz, 10a-C), 132.8 (quat., 8-C), 138.2 (quat., dd, J = 263.5, 5.4 Hz, 4-C), 141.6 
(quat., dd, J = 18.0, 7.8 Hz, 4a-C), 143.9 (quat., dt, J = 275.0, 5.4 Hz, 2-C), 144.2 (quat., 5a-
C), 144.4 (quat., dd, J = 279.2, 13.2 Hz, 1-C), 172.3 (quat., td, J = 19.0, 6.6 Hz, 3-C). 
4.4. Microbiological methods 
Test compound 5-7 was dissolved in a small volume of N-methylpyrrolidone (100µL) and 
Tween 20 (100µL) and incorporated into molten Columbia agar (Oxoid, Basingstoke) to give 
a final concentration of 50mg/L; the use of a surfactant (Tween 20) was necessary to avoid 
precipitation of the substrates during incorporation into the agar medium. The resulting 
chromogenic media were poured into Petri dishes and each solution dried to a gel. The 
resultant agar plates were each inoculated with ten Gram negative, eight Gram positive 
bacteria and two yeasts (from the National Collection of Type Cultures, London, UK): 
colonies of each strain were suspended in sterile deionised water to generate a suspension 
with a turbidity equivalent to 0.5 McFarland units (approximately 1.5 × 10
8 colony forming 
units per mL), as confirmed with a densitometer. One microliter of this suspension was 
inoculated onto the agar plates containing the various substrates using an automated 20 
 
multipoint inoculator. All inoculated plates were incubated at 37°C for 24h and then 
examined visually for the presence of growth and colouration of bacterial colonies. 
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